← Issue №18/ week of Nov 1, 2026/Hepatology

Erythrocyte phosphatidylserine externalization shows greater discriminatory performance than red cell distribution width for early recurrence or progression in hepatocellular carcinoma.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=97 · Oct 29, 2026 · J Gastroenterology · IF 5.7

Erythrocyte phosphatidylserine externalization shows greater discriminatory performance than red cell distribution width for early recurrence or progression in hepatocellular carcinoma.

Basic sciencehepatocellular carcinomabiomarkerbasic sciencetranslational
Clinical takeawayNo clinical action yet: a mechanistic finding in humans with preclinical validation in mice and cell culture.
What it foundPhosphatidylserine (PS) externalization had higher discriminatory performance for 6-month HCC recurrence/progression than RDW-CV (AUC 0.804 vs 0.642).
ContextChallenges the role of RDW as a biomarker in HCC by proposing PS externalization as a superior marker for early recurrence/progression.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Tan M … Huang H · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues